From Wikipedia, the free encyclopedia
Medical condition
Multisystem inflammatory syndrome in children (MIS-C) Other names
Paediatric multisystem inflammatory syndrome (PMIS/PIMS/PIMS-TS)
[1]
Multisystem inflammatory syndrome (MIS) in children and adolescents temporally related to COVID-19
[2]
Kawa-COVID-19
[3]
Systemic inflammatory syndrome in COVID-19 (SISCoV)
[4]
Electron microscope image of
SARS-CoV-2 , the virus responsible for
COVID-19
Specialty
Pediatrics
Symptoms Fever,
abdominal pain , diarrhea,
red eyes , rash, vomiting
[5]
[6]
Complications Heart, lung, kidney, skin, or brain problems
[6] Usual onset 2–6 weeks after COVID-19
[7] Causes
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
[5]
Diagnostic method Based on symptoms and
blood tests after ruling out other causes
[8]
Differential diagnosis
Kawasaki disease
[9] Prevention Protecting children from COVID-19
[6] Management
Supportive care
[8]
Medication
IVIG ,
steroids ,
aspirin
[8]
[10]
Prognosis Long-term outcomes unclear
[10] Frequency 1 in 3,000 after COVID-19
[10] Deaths 1 to 2%
[9]
Multisystem inflammatory syndrome in children (MIS-C ), also known as pediatric inflammatory multisystem syndrome (PIMS ), is a disease in children associated with
COVID-19 .
[5] Symptoms may include ongoing fever plus
abdominal pain , diarrhea,
red eyes , rash, or vomiting.
[5]
[6] Complications may include heart, lung,
kidney , skin, or brain problems.
[6]
It generally occurs around 2 to 6 weeks after COVID-19.
[9]
[7] While it occurs more often in the
obese , those affected are generally otherwise healthy.
[9] Diagnosis is based on symptoms with laboratory signs of inflammation and multiple
body system involvement, after
ruling out other possible causes .
[8]
Serologic testing for prior
SARS-CoV-2 may be useful.
[8] Other conditions that may appear similar include
Kawasaki disease .
[9]
Prevention is by protecting children from COVID-19.
[6] Treatment is primarily
supportive care ; which may include
intravenous fluids ,
inotropes , and support of breathing.
[8] In severe cases
extracorporeal membranous oxygenation (ECMO) may be required.
[8]
IVIG ,
steroids , and
aspirin are often used.
[8]
[10] About 80% of those affected require
intensive care .
[9]
MIS-C affects about 1 in 3,000 children infected by COVID-19.
[10] Those around the age of 9 are most commonly affected.
[10] In the United States it more common in
Black and
Hispanic children.
[10] Death occurred in about 1 to 2% of cases.
[9] The condition was first described in April of 2020.
[10] Adults may develop a similar condition known as
multisystem inflammatory syndrome in adults (MIS-A).
[9]
^
"Rapid risk assessment: Paediatric inflammatory multisystem syndrome and SARS-CoV-2 infection in children" (PDF) .
European Centre for Disease Prevention and Control . 15 May 2020.
Archived from the original on 15 May 2020.
^
"Case Report Form for suspected cases of multisystem inflammatory syndrome (MIS) in children and adolescents temporally related to COVID-19" . www.who.int . World Health Organization.
Archived from the original on 24 June 2020.
^ Pouletty M, Borocco C, Ouldali N, et al. (June 2020).
"Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort" . Annals of the Rheumatic Diseases . 79 (8): 999–1006.
doi :
10.1136/annrheumdis-2020-217960 .
PMC
7299653 .
PMID
32527868 .
S2CID
219607184 .
^ Dhar D, Dey T, Samim MM, et al. (2021).
"Systemic inflammatory syndrome in COVID-19-SISCoV study: systematic review and meta-analysis" . Pediatric Research .
doi :
10.1038/s41390-021-01545-z .
PMC
8128982 .
PMID
34006982 .
^
a
b
c
d Ahmed M, Advani S, Moreira A, et al. (September 2020).
"Multisystem inflammatory syndrome in children: a systematic review" . EClinicalMedicine . 26 : 100527.
doi :
10.1016/j.eclinm.2020.100527 .
ISSN
2589-5370 .
PMC
7473262 .
PMID
32923992 .
S2CID
221494176 .
^
a
b
c
d
e
f
"Multisystem Inflammatory Syndrome (MIS)" . Centers for Disease Control and Prevention . 11 February 2020.
Archived from the original on 13 January 2022. Retrieved 20 January 2022 .
^
a
b Henderson LA, Canna SW, Friedman KG, et al. (July 2020).
"American College of Rheumatology clinical guidance for pediatric patients with multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2 and hyperinflammation in COVID-19. Version 1" . Arthritis & Rheumatology . 72 (11): 1791–1805.
doi :
10.1002/art.41454 .
PMC
7405113 .
PMID
32705809 .
^
a
b
c
d
e
f
g
h
"Multisystem Inflammatory Syndrome (MIS)" . Centers for Disease Control and Prevention . 11 February 2020.
Archived from the original on 16 December 2021. Retrieved 20 January 2022 .
^
a
b
c
d
e
f
g
h
"Children" . COVID-19 Treatment Guidelines .
Archived from the original on 19 July 2020. Retrieved 20 January 2022 .
^
a
b
c
d
e
f
g
h
"Ten Things to Know About MIS-C" . American College of Cardiology .
Archived from the original on 6 January 2022. Retrieved 20 January 2022 .